This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ITGR vs. PEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. PEN: Which Stock Is the Better Value Option?
Why Integer (ITGR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.
Integer (ITGR) Q2 Earnings Lag Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -1.27% and +2.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ECL Unveils ReadyDose Cleaning Program for Southeast Asian Restaurants
by Zacks Equity Research
Ecolab rolls out ReadyDose, a tablet-based cleaning solution to help Southeast Asian restaurants cut waste and boost hygiene.
ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval
by Zacks Equity Research
Intuitive Surgical wins FDA nod for its Vessel Sealer Curved, boosting the da Vinci system's precision and multifunctional capabilities.
ITGR or PEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. PEN: Which Stock Is the Better Value Option?
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
by Zacks Equity Research
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
AMN Stock Gains Post Latest Deals With symplr to Boost Operations
by Zacks Equity Research
AMN Healthcare sells Smart Square to symplr for $75 million and forms a new technology partnership aimed at boosting scheduling efficiency.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
by Zacks Equity Research
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Why Integer (ITGR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Intuitive Surgical's Fifth Generation da Vinci System Receives CE Mark
by Zacks Equity Research
ISRG secures CE mark for its da Vinci 5 system, unlocking European access to its most advanced surgical platform yet.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
COO Stock Declines Despite Strong Core Growth Amid Fertility Woes
by Zacks Equity Research
The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
by Zacks Equity Research
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
by Zacks Equity Research
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
Walgreens Q3 Earnings Top Estimates, Stock Up, Gross Margin Declines
by Zacks Equity Research
WBA tops Q3 earnings and sales estimates and lifts shares, but the gross margin contracts, and guidance is withdrawn.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
ITGR vs. PEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. PEN: Which Stock Is the Better Value Option?
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications
by Zacks Equity Research
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
by Zacks Equity Research
Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.